WinstonWınston
CS Diagnostics logo

CS Diagnostics

CSDX
32
Medical - Devices · Healthcare
Price
$0.06
+0.01 (+17.00%)
Market Cap
$14.6M
Winston Score
32
Winston is serious
Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+86274.9% over 5y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 289K (2020) → 250.0M (2025)

CS Diagnostics Corp. (CSDX) does not appear in widely available public financial databases, and reliable details about its products, customers, or operations are not available. The company operates in the medical devices industry within the healthcare sector, but its specific diagnostic tools, target markets, and geographic footprint are not clearly documented in public sources.

The financial data provided shows zero gross margin, zero operating margin, and a market cap effectively at zero, which suggests the company may be pre-revenue, very early stage, or thinly traded. Companies at this stage typically face significant risks including limited cash runway, unproven products, and heavy reliance on future funding rounds to continue operations. Investors should be aware that very small or early-stage medical device companies carry substantially higher uncertainty than established peers, and independent verification of this company's business status is strongly recommended before drawing any conclusions.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
100.0%
Premium pricing power — 100.0% gross margin
Operating Margin
-41.5%
Losing money on operations — -41.5%
ROCE
0.0%
Weak — 0.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-100.0%
Shrinking sales (-100.0% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
9%
Weak — only 9% of profit becomes cash
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
100.00x
Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
146.3x
Expensive — P/E 146.3

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial